在癌症治疗中使用抗体-药物联合体:机制和临床研究
Jun He1, Xianghua Zeng2, Chunmei Wang2
1Department of General Surgery Jiande Branch of the Second Affiliated Hospital, School of Medicine, Zhejiang University Jiande Zhejiang China.
抗体-药物联合体 (ADC) 通过向瘤细胞输送细胞毒药物,提供向癌症治疗. 尽管取得了进展,但耐药性等挑战需要对新的ADC策略和组合疗法进行持续研究,以提高疗效.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 抗体-药物结合剂 (ADC) 是一种先进的治疗方法,将单克隆抗体与细胞毒性有效载荷相结合.
- ADCs利用抗体介导向来选择性地将药物通过内细胞分裂传递给瘤细胞.
- 这种有针对性的方法旨在提高抗瘤疗效,同时尽量减少对健康组织的损害.
研究的目的:
- 提供对抗体-药物合物 (ADC) 开发的全面审查.
- 讨论ADC组成,标选择和临床应用方面的进展.
- 探索抗药性机制和克服它们的策略,包括新的ADC成分和组合疗法.
主要方法:
- 对ADC研究的历史和最近发展的文献综述.
- 对ADC结构,作用机制和临床试验数据的分析.
- 检查新兴趋势,包括新型标记,链接器,有效载荷和组合策略.
主要成果:
- 在ADC开发方面取得了重大进展,有许多候选药物和已批准的治疗方法用于各种癌症.
- 已经研究了300多个ADC,突出了该领域的广泛研究.
- 新出现的挑战包括来自抗原表达,ADC处理和有效载荷的治疗耐药性.
结论:
- 抗瘤剂 (ADC) 是一种强大且不断发展的抗瘤剂.
- 通过新的ADC设计和组合疗法来解决耐药性机制对于未来的成功至关重要.
- 对ADC组件和治疗策略的持续创新有望改善癌症治疗结果.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Phase II Conjugation Reactions: Overview
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
